Mayo Clinic Laboratory and Pathology Research Roundup: Oct. 3

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.

Featured Abstract

Radical Nephrectomy with or without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-Based Analysis

Original Title: 89-76T; Box: 6.8Mayo Clinic researchers conducted a study to evaluate the association of lymph node dissection (LND) with oncologic outcomes among patients undergoing radical nephrectomy for nonmetastatic renal cell carcinoma (RCC). In the overall cohort, LND was not significantly associated with a reduced risk of distant metastases, cancer-specific mortality (CSM), or all-cause mortality (ACM). Moreover, LND was not associated with improved oncologic outcomes even among patients at increased risk of pN1 disease. Among patients who underwent LND, the extent of LND was not significantly associated with the development of distant metastases, CSM, or ACM. Reasearchers did not identify an oncologic benefit to LND in the overall cohort or among patients at increased risk of nodal disease. Lymph node dissection does not appear to provide a therapeutic benefit in patients with nonmetastatic renal cell carcinoma. The study was published in European Urology

Published to PubMed This Week

brentwestra (@brentwestra)


Brent Westra is a Marketing Segment Manager at Mayo Clinic Laboratories. He leads marketing strategies for product management and specialty testing along with new media innovations. Brent has worked at Mayo Clinic since 2011.